Elucidating the true structure of depression is necessary if we are to advance our understanding and treatment options. Central to the issue of structure is whether depression represents discrete types or occurs on a continuum. Nature almost universally operates on the basis of continuums, whereas human perception favors discrete categories. This reality might be formalized into a ‘continuum principle': natural phenomena tend to occur on a continuum, and any instance of hypothesized discreteness requires unassailable proof. Research evidence for discrete types falls far short of this standard, with most evidence supporting a continuum. However, quantitative variation can yield qualitative differences as an emergent property, fostering the appearance of discreteness. Depression as a continuum is best characterized by duration and severity dimensions, with the latter understood in terms of depressive inhibition. In the absence of some degree of cognitive, emotional, social, and physical inhibition, depression should not be diagnosed. Combining the dimensions of duration and severity provides an optimal way to characterize the quantitative and related qualitative aspects of depression and to describe the overall degree of dysfunction. The presence of other symptom types occurs when anxiety, hypomanic/manic, psychotic, and personality continuums interface with the depression continuum.

Keywords:
Depression, Melancholia, Endogenous depression, Reactive depression, Major depression, Minor depression, Dysthymia, Discrete, Dimensions
1.
Parker G, Hall W, Boyce P, Hadzi-Pavlovic D, Mitchell P, Wilhelm K: Depression sub-typing: unitary, binary, or arbitrary? Aust NZ J Psychiatry 1991;25:63-76.
2.
Parker G: A case for reprising and redefining melancholia. Can J Psychiatry 2013;58:183-189.
3.
Benazzi F: Various forms of depression. Dial Clin Neurosci 2006;8:151-161.
4.
Kessing LB: Epidemiology of subtypes of depression. Acta Psychiatr Scand 2007;115(suppl 433):85-89.
5.
Paykel ES: Basic concepts of depression. Dial Clin Neurosci 2008;10:279-289.
6.
Kessing LV: Endogenous, reactive and neurotic depression - diagnostic stability and long-term outcome. Psychopathology 2004;37:124-130.
7.
Healy D: Melancholia: past and present. Can J Psychiatry 2013;58:190-194.
8.
First MB, Frances A, Pincus HA: DSM-IV-TR: Handbook of Differential Diagnosis. Washington, American Psychiatric Publishing, 2002.
9.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5. Washington, American Psychiatric Publishing, 2013.
10.
World Health Organization: The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, World Health Organization, 1992.
11.
Kiloh LG, Andrews G, Neilson M, Bianchi GN: The relationship of the syndromes called endogenous and neurotic depression. Br J Psychiatry 1972;121:183-196.
12.
Parker G, Blignault I, Manicavasagar V: Neurotic depression: delineation of symptom profiles and their relation to outcome. Br J Psychiatry 1988;152:15-23.
13.
Shorter E: A History of Psychiatry. Toronto, John Wiley & Sons, 1997.
14.
Eysenck HJ: The classification of depressive illness. Br J Psychiatry 1970;117:241-250.
15.
Su S, Sun M, Wen M, Lin C, Chen Y, Hung Y: Brain-derived neurotrophic factor, adiponectin, and proinflammatory markers in various subtypes of depression in young men. Int J Psychiatry Med 2011;42:211-226.
16.
Welch GW, Ellis PM: FACTOREP: a new tool to explore the dimensions of depression. J Affect Disord 1991;21:101-108.
17.
Bech P: Rating scales for mood disorders: applicability, consistency, and construct validity. Acta Psychiatr Scand Suppl 1988;345:45-55.
18.
Bronisch T, Klerman GL: The current status of neurotic depression as a diagnostic category. Psychiatr Dev 1988;6:245-275.
19.
O'Leary D: The endogenous subtype and naturalistic course in depression. J Affect Disord 1996;41:117-123.
20.
Ramana R, Paykel ES, Cooper Z, Hayhurst H, Saxty M, Surtees PG: Remission and relapse in major depression: a two-year prospective follow-up study. Psychol Med 1995;25:1161-1170.
21.
Surtees PG, Barkley C: Future imperfect: the long-term outcome of depression. Br J Psychiatry 1994;164:327-341.
22.
Brodaty H, Luscombe G, Peisah C, Anstey K, Andrews G: A 25-year longitudinal, comparison study of the outcome of depression. Psychol Med 2001;31:1347-1359.
23.
Rhebergen D, Graham R: The re-labelling of dysthymic disorder to persistent depressive disorder in DSM-5: old wine in new bottles? Curr Opin Psychiatry 2014;27:27-31.
24.
Rhebergen D, Graham R, Hadzi-Pavlovic D, Stek M, Friend P, Barrett M, Parker G: The categorisation of dysthymic disorder: can its constituents be meaningfully apportioned? J Affect Disord 2012;143:179-186.
25.
Newman SC, Bland RC: A population-based family study of minor depression. Depress Anxiety 2009;26:389-392.
26.
Angst J, Sellaro R, Merikangas KR: Depressive spectrum diagnoses. Compr Psychiatry 2000;41(suppl):39-47.
27.
Angst J, Merikangas KR: The depressive spectrum: diagnostic classification and course. J Affect Disord 1997;45:31-39.
28.
Judd LL, Akiskal HS, Maser JD: A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998;55:694-700.
29.
Harris M, Farquhar F, Healy D, LeNoury J, Baker D, Whitaker C, Linden S, Green P, Roberts AP: The incidence and prevalence of admissions for melancholia in two cohorts (1875-1924 and 1995-2005). J Affect Disord 2011;134:45-51.
30.
Harris M, Farquhar F, Healy D, LeNoury J, Linden S, Hughes JA, Roberts AP: The morbidity and mortality linked to melancholia: two cohorts compared, 1875-1924 and 1995-2005. Hist Psychiatry 2013;24:3-14.
31.
Parker G, Fletcher K, Barrett M, Synnott H, Breakspear M, Rees AM, Hadzi-Pavlovic D: Inching toward Bethlehem: mapping melancholia. J Affect Disord 2010;123:291-298.
32.
Parker G, McCraw S, Blanch B, Hadzi-Pavlovic D, Synnott H, Rees AM: Discriminating melancholic and non-melancholic depression by prototypic clinical features. J Affect Disord 2013;144:199-207.
33.
Darwin C: The Origin of Species. New York, Signet Classic, 1858/1958.
34.
Kinsey AC, Pomeroy WB, Martin CE: Sexual Behavior in the Human Male. Philadelphia, WB Saunders, 1948.
35.
Kinsey AC, Pomeroy WB, Martin CE, Gebhard PH: Sexual Behavior in the Human Female. Philadelphia, WB Saunders, 1953.
36.
Schotte CK, Maes M, Cluydts R, Cosyns P: Cluster analytic validation of the DSM melancholic depression. The threshold model: integration of quantitative and qualitative distinctions between unipolar depressive subtypes. Psychiatry Res 1997;71:181-195.
37.
Kessing LV: Severity of depressive episodes according to ICD-10: prediction of risk of relapse and suicide. Br J Psychiatry 2004;184:153-156.
38.
Marneros A: Origin and development of concepts of bipolar mixed states. J Affect Disord 2001;67:229-240.
39.
Carlson GA, Goodwin FK: The stages of mania: a longitudinal analysis of the manic episode. Arch Gen Psychiatry 1973;28:221-228.
40.
Cassidy F, Murry E, Forest K, Carroll BJ: Signs and symptoms of mania in pure and mixed episodes. J Affect Disord 1998;50:187-201.
41.
Akiskal HS, Hantouche EG, Bourgeois ML, Azorin JM, Sechter D, Allilaire JF, Lancrenon S, Fraud JP, Liliane CD: Gender, temperament, and the clinical picture in dysphoric mixed mania: findings from a French national study (EPIMAN). J Affect Disord 1998;50:175-186.
42.
Benazzi F, Akiskal HS: Delineating bipolar II mixed states in the Ravenna-San Diego collaborative study: the relative prevalence and diagnostic significance of hypomanic features during major depressive episodes. J Affect Disord 2001;67:115-122.
43.
Bauer MS, Whybrow PC, Gyulai L, Gonnel J, Yeh HS: Testing definitions of dysphoric mania and hypomania: prevalence, clinical characteristics and inter-episode stability. J Affect Disord 1994;32:201-211.
44.
Freeman MP, McElroy SL: Clinical picture and etiologic models of mixed states. Psychiatr Clin North Am 1999;22:535-546.
45.
Fava M, Rankin MA, Wright EC: Anxiety disorders in major depression. Compr Psychiatry 2000;41:97-102.
46.
Cochrane N: A contribution from the field of psychodynamics to the controversy over reactive and endogenous depression. Br J Med Psychol 1977;50:87-94.
47.
Himmelhoch JM: Social anxiety, hypomania and the bipolar spectrum: data, theory and clinical issues. J Affect Disord 1998;50:203-213.
48.
Benazzi F: Factor structure of recalled DSM-IV hypomanic symptoms of bipolar disorder. Compr Psychiatry 2004;45:441-446.
49.
Benazzi F: Is overactivity the core feature of hypomania in bipolar II disorder? Psychopathology 2007;40:54-60.
50.
Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA: Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000;157:549-559.
51.
Elvevag B, Goldberg TE: Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000;14:1-21.
52.
Fiszdon JM, Richardson R, Greig T, Bell MD: A comparison of basic and social cognition between schizophrenia and schizoaffective disorder. Schizophr Res 2007;91:117-121.
53.
Gray JA: Perspectives on anxiety and impulsivity: a commentary. J Res Pers 1987;21:493-509.
54.
Fowles DC: Psychophysiology and psychopathology: a motivational approach. Psychophysiology 1988;25:373-391.
55.
Kasch KL, Rottenberg J, Arnow BA, Gotlib IH: Behavioral activation and inhibition systems and the severity and course of depression. J Abnorm Psychol 2002;111:589-597.
56.
Johnson SL, Sandrow D, Meyer B, Winters R, Miller I, Solomon D, Keitner G: Increases in manic symptoms after life events involving goal attainment. J Abnorm Psychol 2000;109:721-727.
57.
Campbell-Sills L, Liverant GI, Brown TA: Psychometric evaluation of the behavioral inhibition/behavioral activation scales in a large sample of outpatients with anxiety and mood disorders. Psychol Assess 2004;16:244-254.
58.
Mineka S, Watson D, Clark LA: Comorbidity of anxiety and unipolar mood disorders. Ann Rev Psychol 1998;49:377-412.
59.
Scholten MR, van Honk J, Aleman A, Kahn RS: Behavioral inhibition system (BIS) and the behavioral activation system (BAS) and schizophrenia: relationship with psychopathology and physiology. J Psychiatr Res 2006;40:638-645.
60.
Bowins BE: Hypomania: a depressive inhibition override defense mechanism. J Affect Disord 2008;109:221-232.
61.
Azorin JM, Kaladjian A, Fakra E, DaFonseca D, Adida M, Maurel M, Richieri R, Bottai T, Pringuey D: Gene-environment interactions in affective disorders. Encephale 2010;36(suppl 6):162-172.
62.
Du X, Pang TY, Hannan AJ: A tale of two maladies? Pathogenesis of depression with and without the Huntington's disease gene mutation. Front Neurol 2013;4:81.
63.
Treadway MT, Pizzagalli DA: Imagining the pathophysiology of major depressive disorder - from localist to circuit-based analysis. Biol Mood Anxiety Disord 2014;4:5.
64.
Pandya M, Altinay M, Malone DA, Anand A: Where in the brain is depression? Curr Psychiatry Rep 2012;14:634-642.
65.
Carver CL, White TL: Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: the BIS/BAS scales. J Pers Soc Psychol 1994;67:319-333.
66.
Bowins BE: Augmenting behavioural activation treatment with the behavioural activation and inhibition scales. Behav Cogn Psychother 2012;40:233-237.
67.
Hopko DR, Lejuez CW, Ruggiero KJ, Eifert GH: Contemporary behavioral activation treatments for depression: procedures, principles, and progress. Clin Psychol Rev 2003;23:699-717.
68.
Jacobson NS, Dobson KS, Truax PA, Addis ME, Koerner K, Gollan JK: A component analysis of cognitive-behavioral treatment for depression. J Consult Clin Psychol 1996;64:295-304.
69.
Lejuez CW, Hopko DR, Hopko SD: A brief behavioral activation treatment for depression. Behav Modif 2001;25:255-286.
70.
Kanter JW, Puspitasari AJ, Santos MM, Nagy GA: Behavioural activation: history, evidence, and promise. Br J Psychiatry 2012;200:361-363.
71.
Ly KH, Truschel A, Jarl L, Magnusson S, Windahl T, Johansson R, Carlbring P, Andersson G: Behavioural activation versus mindfulness-based guided self-help treatment administered through a smartphone application: a randomised controlled trial. BMJ 2013;4:e003440.
72.
McEvoy P, Law A, Bates R, Hylton K, Mansell W: Using behavioural activation in the treatment of depression: a control theory perspective. J Psychiatr Ment Health Nurs 2013;20:890-895.
73.
Chartier S, Provencher MD: Behavioural activation for depression: efficacy, effectiveness and dissemination. J Affect Disord 2013;145:292-299.
74.
Davidson K, Kaplan B: Nutrient intakes are correlated with overall psychiatric functioning in adults with mood disorders. Can J Psychiatry 2012;57:85-92.
75.
Hansen V, Skre I, Lund E: What is this thing called ‘SAD'? A critique of the concept of seasonal affective disorder. Epidemiol Psychiatr Soc 2008;17:120-127.
76.
Watson D: Rethinking the mood and anxiety disorders: a quantitative hierarchical model for DSM-V. J Abnorm Psychol 2005;114:522-536.
77.
Bowins BE: Psychological defense mechanisms: a new perspective. Am J Psychoanal 2004;64:1-26.
78.
Bowins BE: How psychiatric treatments can enhance psychological defense mechanisms. Am J Psychoanal 2006;66:173-194.
79.
Finlay-Jones R, Brown G: Types of stressful life event and the onset of anxiety and depressive disorders. Psychol Med 1981;11:803-815.
80.
Shrout P, Link B, Dohrenwend B, Skodol A, Stueve A, Mirotznik J: Characterizing life events as risk factors for depression: the role of fateful loss events. J Abnorm Psychol 1989;98:460-467.
81.
Eley T, Stevenson J: Specific life events and chronic experiences differentially associated with depression and anxiety in young twins. J Abnorm Child Psychol 2000;28:383-394.
82.
Beck A: Cognitive therapy: a 30-year retrospective. Am Psychol 1991;46:368-375.
83.
Lazarus R: Cognition and emotion in motivation. Am Psychol 1991;46:352-367.
84.
Lazarus R: On the primacy of cognition. Am Psychol 1984;39:124-129.
85.
Clore GL, Ortony A: Cognition in emotion: always, sometimes, or never?; in Lane RD, Nadel L (eds): Cognitive Neuroscience of Emotion. New York, Oxford University Press, 2000, pp 24-61.
86.
Schneier FR, Blanco C, Antia SX, Liebowitz MR: The social anxiety spectrum. Psychiatr Clin North Am 2002;25:757-774.
87.
Akiskal HS: The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol 1996;16:4S-15S.
88.
Akiskal HS: Searching for behavioral indicators of bipolar II in patients presenting with major depressive episodes: the ‘red sign,' the ‘rule of three' and other biographic signs of temperamental extravagance, activation and hypomania. J Affect Disord 2005;84:279-290.
89.
Weissman MM, Myers JK: Affective disorders in a US urban community. Arch Gen Psychiatry 1978;35:1304-1311.
90.
Chapman LJ, Chapman JP: Scales for rating psychotic and psychotic-like experiences as continua. Schizophren Bull 1980;6:476-489.
91.
Strauss JS: Hallucinations and delusions as points on continua function. Arch Gen Psychiatry 1969;21:581-586.
92.
Bowins BE: A cognitive regulatory control model of schizophrenia. Brain Res Bull 2011;85:36-41.
93.
Bernstein DP, Iscan C, Maser J: Opinions of personality disorder experts regarding the DSM-IV personality disorders classification. J Personal Disord 2007;21:536-551.
94.
Weeks J: Sexuality and Its Discontents. London, Routledge and Kegan Paul, 1985.
95.
Thorp J: The social construction of homosexuality. Phoenix 1992;46:54-65.
96.
Herdt GH: Cross-cultural forms of homosexuality and the concept ‘gay'. Psychiatr Ann 1988;18:37-39.
97.
Bhugra D, McMullen I, Popelyuk D: Paraphilias across cultures: contexts and controversies. J Sex Res 2010;47:242-262.
98.
Storms MD: Theories of sexual orientation. J Pers Soc Psychol 1980;38:783-792.
99.
Shively MG, De Cecco JP: Components of sexual identity. J Homosex 1977;3:41-48.
100.
Muscarella F: The homoerotic behavior that never evolved. J Homosex 1999;37:1-18.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.